A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 18 Jul 2017 Status changed from recruiting to completed.
    • 29 Jun 2017 Top-line results (n = 476) published in a Cara Therapeutics media release.
    • 09 Mar 2017 Top-line data from this trial is expected in the second quarter of 2017, according to a Cara Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top